TrialLung cancer (Amsterdam, Netherlands)2017

Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC.

David E Gerber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.